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ABSTRACT  
BACKGROUND: A relationship between non-neurological autoimmune (NNAI) disorders and 
psychosis has been widely reported, but not yet subjected to meta-analysis. We conducted the 
first meta-analysis examining the association between NNAI disorders and psychosis, and 
investigated the effect of (a) temporality (as determined by study design), (b) psychiatric 
diagnosis, and (c) specific autoimmune disorders. 
METHODS: Major databases were searched for articles published until April 2018. Thirty-one 
studies, comprising data for >25 million individuals, were eligible. Using random effects models, 
we examined the overall association between all NNAI disorders and psychosis, rheumatoid 
arthritis was examined separately given the well-established negative association with 
psychosis. Stratified analyses investigated the effect of temporality, psychiatric diagnosis, and 
specific NNAI disorders.  
RESULTS: We observed a positive, overall association between NNAI disorders and psychosis 
(odds ratio = 1.26; 95% CI: 1.12 - 1.41) that was consistent across study designs and psychiatric 
diagnoses; however, considerable heterogeneity was detected (I
2
 = 88.09). Patterns varied 
across individual NNAI disorders; associations were positive for pernicious anaemia (1.91; 1.29 - 
2.84), pemphigoid (1.90; 1.62 - 2.24), psoriasis (1.70; 1.51 - 1.91), coeliac disease (1.53; 1.12 - 
2.10), and Graves’ disease (1.33; 1.03 - 1.72), and negative for ankylosing spondylitis (0.72; 0.54 
- 0.98) and rheumatoid arthritis (0.65; 0.50 - 0.84). 
CONCLUSIONS: Whilst we observed a positive, overall association between NNAI disorders and 
psychosis, this was not consistent across all NNAI disorders. Specific factors, including distinct 
inflammatory pathways, genetic influences, autoantibodies targeting brain proteins, or 
exposure to corticosteroid treatment, may therefore underlie this association.   
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INTRODUCTION 
Findings from studies conducted over the past six decades have been used to support the 
claim that a relationship exists between non-neurological autoimmune disorders (NNAI, i.e., 
those largely affecting peripheral systems) and psychosis. In the 1950s, it was first observed that 
rheumatoid arthritis was less common among individuals with psychosis than in the general 
population (1, 2). Conversely, subsequent studies reported that other NNAI disorders, including 
coeliac disease, systemic lupus erythematous, and autoimmune thyroid disorders, were more 
prevalent among individuals with psychosis (3-6). The most convincing evidence has come from 
several large-scale population studies which have demonstrated positive associations between 
schizophrenia and a range of autoimmune disorders (7-9). Whilst there has been increased 
interest in this topic in light of evidence of altered immune system function in psychosis (10-12), 
the overall association between NNAI disorders and psychosis has yet to be investigated using 
meta-analytic techniques.  
Quantifying the degree of association between NNAI disorders and psychosis, and the 
extent to which this varies across study designs, specific psychiatric diagnosis, and individual 
NNAI disorders, may help to elucidate the mechanisms that underlie any relationship and 
ultimately lead to the identification of more effective intervention strategies. Disentangling the 
temporal nature of this relationship is an important first step to determining whether these 
disorders simply co-occur more commonly than expected, or whether NNAI disorders in fact 
increase the risk for psychosis. To this end, our study aimed to conduct the first meta-analysis 
examining the association between NNAI disorders and psychosis. Only NNAI disorders were 
included due to the well-established psychiatric manifestations of neurological autoimmune 
disorders. In the primary analysis, we examined effect sizes obtained from all studies 
irrespective of design or diagnostic outcome; however, given the well-documented negative 
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association between rheumatoid arthritis and psychosis, effect sizes for this disorder were 
examined in isolation. Stratified analyses were conducted to further examine the extent to 
which (a) temporality (as determined by study design), (b) specific psychiatric diagnoses 
(schizophrenia vs. more broadly defined psychosis vs. non-schizophrenia psychosis), and (c) 
specific NNAI disorders, influenced the magnitude and consistency of any effect.  
METHODS AND MATERIALS 
Search Strategy 
As far as possible, the search strategy was conducted in accordance with the meta-analysis 
of observational studies in epidemiology (MOOSE) guidelines (13), as detailed in Supplementary 
Table S1. In brief, PubMed, PsycINFO, EMBASE, WorldCat dissertations and Theses, and Global 
Health were searched for all articles published until April 2018, with reference lists of review 
articles manually searched. Searches included the terms “psychosis” or “schizophrenia” or “non-
affective psychosis” or “clinical psychotic symptoms” combined with “autoimmune disorders” or 
“autoimmune diseases” or “XXX”, the latter representing 37 individual NNAI disorders (see 
Supplementary Table S2). Autoimmune disorders included in the search strategy were selected 
a priori from the American Autoimmune and Related Diseases Association [AARDA (14)] all 
disorders were cross-checked against known neurological disorders, as listed by the American 
Academy of Neurology (15), and only those that did not appear here were deemed eligible for 
inclusion. Full texts of articles were retrieved as necessary and study authors were contacted 
where these were unavailable.  
Selection Criteria  
Detailed inclusion and exclusion criteria are provided in Supplementary Table S3. After a 
preliminary screen (title and abstract) to exclude studies that clearly did not meet eligibility 
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criteria, two of the authors (A.E.C and S.H.) reviewed the full text of all potentially eligible 
studies to determine inclusion. Disagreements were resolved by discussion with all study 
authors.  
Data Extraction 
Two researchers (A.E.C and S.H.) independently extracted information on year of 
publication, psychiatric diagnosis, autoimmune disorders, country, study design, data source, 
sample size, mean or median age of sample, participant sex, matching factors, and outcome 
measure (prevalence or incidence). To examine the effect of temporality, all eligible studies 
were categorised as follows: (1) studies examining the comorbidity of NNAI disorders and 
psychosis (type A); (2) studies in which the autoimmune disorder preceded the onset or 
measurement of the psychotic disorder (type B); and (3) studies in which the psychotic disorder 
preceded the onset or measurement of the autoimmune disorder (type C).  
We included studies providing prevalence or incidence data on the basis that psychotic and 
autoimmune disorders are both rare, thus odds and risk ratios are likely comparable (16). To 
pool data across studies reporting different effect size measures, we extracted raw data from all 
eligible studies as follows: the number of individuals with both psychosis and an autoimmune 
disorder (a), the number of individuals with psychosis who did not have an autoimmune 
disorder (b), the number of individuals without psychosis who had an autoimmune disorder (c), 
and the number of individuals who had neither psychosis nor an autoimmune disorder (d). 
Extracted data were used to compute odds ratios ((a/c)/(b/d)) with 95% confidence intervals; a 
continuity correction of 0.5 was applied to cells with zero counts (17). Thus, our pooled effect 
sizes represent raw (unadjusted) associations. 
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Where the stated aim of the study was to examine ‘autoimmune disorders’, and efforts 
were made by the authors to distinguish these from similar disorders with other (non-
autoimmune) causes, we extracted data for all disorders classified as autoimmune by the 
authors (excepting those with a neurological basis); this included various forms of anaemia (8, 9, 
18). For studies reporting data for both schizophrenia and more broadly defined psychosis 
(where the latter included schizophrenia) we subtracted schizophrenia cases from the total 
number of psychosis cases to obtain mutually exclusive groups. Where studies examined 
multiple NNAI disorders and/or more than one psychiatric outcome, data were extracted for 
each NNAI disorder/psychiatric outcome separately such that a single study could provide 
multiple effect sizes. Authors were contacted when these data were not reported in the 
publication, with data provided for some studies (4, 18-22), but not others (7, 23-25).  
Eligible studies were assessed for quality by the first author (A.E.C.) using a modified 
version of the Newcastle-Ottawa Scale [NOS (26)]. The NOS provides separate assessment 
criteria for cross-sectional, case-control, and cohort studies, covering three methodological 
domains (selection criteria, comparability, and measurement of exposure/outcome). Scoring 
criteria were amended such that the maximum score available for each study design was eight 
(see Supplementary Table S4).  
Statistical Analyses 
Meta-analyses were conducted using Comprehensive Meta Analysis Software version 3.0. 
Given that the studies varied with respect to design and specific autoimmune disorders 
examined, we anticipated that the ‘true effect’ would vary across studies; all analyses were 
therefore conducted using a random-effects model with inverse weighting applied (27). 
Stratified analyses were used to explore potential mechanisms and sources of heterogeneity.  
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We first examined the overall association between NNAI disorders and psychosis, excluding 
effect sizes pertaining to rheumatoid arthritis. Next, we explored the effect of temporality by 
conducting analyses for each of the separate study design types defined above (A, B, and C). In 
the third step, we stratified by psychiatric diagnosis to determine whether the association with 
autoimmune disorders varied according to whether the outcome was schizophrenia, more 
broadly defined psychosis (including schizophrenia), or non-schizophrenia psychosis. Finally, 
meta-analyses were conducted for individual autoimmune disorders where more than three 
effect sizes were available. Statistical significance was set at P < 0.05 (2-tailed) for all analyses. 
Heterogeneity was assessed via the Cochran Q statistic (to identify statistically significant 
heterogeneity) and the I
2 
statistic (to estimate the percentage of the variability in odds ratios 
due to heterogeneity) where classification of the latter as likely ‘unimportant’ (0-40%), 
‘moderate’ (30-60%),  ‘substantial’ (50-90%), or  ‘considerable’ (75-100%) was dependent on the 
magnitude/direction of effects and statistical significance of heterogeneity (28). Given the 
problems associated with applying statistical tests to assess small sample bias (“publication 
bias”) in meta-analyses with binary outcomes, particularly when significant heterogeneity is 
present (29), small sample bias was assessed visually by means of a funnel plot for analyses with 
10 or more effect sizes. 
RESULTS 
Search Results  
Thirty publications (4, 8, 9, 18-22, 30-51) yielding 31 studies and 107 effect sizes, met 
inclusion criteria (see Figure 1). This included one study originally published as conference 
abstract [(18) later withdrawn as the author was unable to attend], but for which statistical 
outputs for all analyses were kindly provided by the study author. Study details are provided in 
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Table 1; the total number of individuals included across all studies was 25,041,429. Quality 
rating scores ranged from 2-8 (mean ± SD: 5.06 ± 1.29).  
[Insert Figure 1 here] 
[Insert Table 1 here]  
Global Association between Autoimmune Disorders and Psychosis 
An analysis was first conducted to test the global association between all NNAI disorders, 
excluding rheumatoid arthritis, and psychosis. As shown in Figure 2, a significant positive 
association was observed (OR = 1.26; 95% CI: 1.12 to 1.41); however, considerable between-
study heterogeneity was detected (see Table 2). The funnel plot (Supplementary Figure S1, 
Panel A) showed no evidence of asymmetry.  
[Insert Figure 2 here] 
[Insert Table 2 here]  
  
Stratification by Temporal Relationship 
The temporal association between NNAI autoimmune disorders (excluding rheumatoid 
arthritis) and psychosis was investigated by conducting separate meta-analyses for studies 
examining the comorbidity of these disorders (type A), studies in which the autoimmune 
disorder preceded psychosis (type B), and studies in which psychosis preceded the autoimmune 
disorder (type C). Significant positive associations were observed for all three study types: A (OR 
= 1.20; 95% CI: 1.06 to 1.35), B (OR = 1.43; 95% CI: 1.04 to 1.95), C (OR = 1.55; 95% CI: 1.01 to 
2.38) although there was considerable heterogeneity between studies within each type (Table 
2).   
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Stratification by Psychiatric Outcome 
Of the 90 effect sizes included in the main analysis (i.e., excluding rheumatoid arthritis), 77 
examined schizophrenia, 8 a more broadly defined psychosis outcome that included 
schizophrenia, and 5 non-schizophrenia psychosis. As shown in Table 2, odds ratios were 
positive and statistically significant for all three psychiatric diagnostic outcomes: schizophrenia 
(OR = 1.21, 95% CI: 1.04 to 1.40), broadly-defined psychosis (OR = 1.81, 95% CI: 1.39 to 2.37), 
non-schizophrenia psychosis (OR = 1.38, 95% CI: 1.01 to 1.88). However, heterogeneity was 
considerable for all three outcomes. 
Stratification by Autoimmune Disorder 
Separate meta-analyses were conducted for individual autoimmune disorders where more 
than three effect sizes were available for analysis (Table 2). A significant positive association was 
observed for pemphigoid (OR = 1.90, 95% CI: 1.62 to 2.24), pernicious anaemia (OR = 1.91, 95% 
CI: 1.29 to 2.84), psoriasis (OR = 1.70, 95% CI: 1.51 to 1.91), coeliac disease (OR = 1.53; 95% CI: 
1.12 to 2.10), and Graves’ disease (OR = 1.33, 95% CI: 1.03 to 1.72). Significant negative 
associations with psychosis were observed for both ankylosing spondylitis (OR = 0.72, 95% CI: 
0.54 to 0.98) and rheumatoid arthritis (OR = 0.65, 95% CI: 0.50 to 0.84, see Figure 3). No 
significant associations with psychosis were observed for alopecia areata, Crohn’s disease, 
polymyalgia rheumatica, systemic lupus erythematosus (SLE), type 1 diabetes, or ulcerative 
colitis. Of the seven autoimmune disorders significantly associated with psychosis, 
heterogeneity estimates were possibly unimportant-to-moderate, and not statistically 
significant, for pernicious anaemia, ankylosing spondylitis, coeliac disease, Graves’ disease, and 
pemphigoid, whilst significant, moderate-to-substantial heterogeneity was detected for 
psoriasis and rheumatoid arthritis (Table 2). Visual inspection of the funnel plot for rheumatoid 
arthritis indicated no substantial asymmetry (Supplementary Figure S1, Panel B).  
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[Insert Figure 3 here] 
DISCUSSION 
This is the first meta-analysis to examine the association between multiple non-
neurological autoimmune disorders and psychosis. Our primary analysis (which excluded 
rheumatoid arthritis), showed evidence of a generic, positive association between NNAI 
disorders and psychosis. Whilst the overall effect size was small (OR = 1.26), and substantial 
heterogeneity was detected, this positive association was consistent across study designs and 
psychiatric outcomes. Analyses conducted for separate NNAI disorders showed significant, 
positive associations for pernicious anaemia, pemphigoid, psoriasis, coeliac disease, and Graves’ 
disease, and significant negative associations for ankylosing spondylitis and rheumatoid arthritis.   
Stratified analyses demonstrated that not only is there increased comorbidity between 
NNAI disorders and psychosis (type A), but that NNAI disorders increase the risk for subsequent 
psychosis (type B) and vice versa (type C). Similarly, the positive association we observed was 
consistent across psychiatric diagnoses, despite the fact that analyses performed in these 
subgroups were likely underpowered. However, heterogeneity was not improved when we 
stratified by these variables, which likely reflects the wide range of NNAI disorders examined. 
Stratification by NNAI disorder improved heterogeneity estimates for some conditions but not 
others (alopecia areata, Crohn’s disease, psoriasis, rheumatoid arthritis, SLE, and type 1 
diabetes). Study factors (e.g., country and data source) and participant factors (sex and 
treatment) may contribute to the residual heterogeneity observed within these NNAI disorders. 
Our analyses were restricted to studies which provided raw data that could be used to 
calculate odds ratios, thereby precluding us from including data from two nationwide studies, 
each examining multiple NNAI disorders, that specifically addressed temporal effects (7, 23). 
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Benros and colleagues reported that the presence of any prior autoimmune disorder increased 
the risk of schizophrenia by 1.29 fold (7), whilst schizophrenia increased the risk for subsequent 
autoimmune disorder by 1.53 fold (23). As these results are consistent with the summary odds 
ratios that we derived from type B (OR = 1.43) and type C (OR = 1.55) studies, it is unlikely that 
these data would have altered the significant positive associations that we observed, although 
the statistical significance of our type C analyses (which were likely underpowered) may have 
increased.  
Multiple factors have been suggested to underlie the observed association between NNAI 
and psychosis, including inflammation, shared genetic vulnerability, predisposing infections, and 
brain-reactive antibodies (10). Several lines of evidence support the inflammatory hypothesis of 
psychosis. First, elevated levels of inflammatory markers (i.e., C-reactive protein and cytokines) 
and proinflammatory cells (e.g., T helper cells 17: Th17) have been observed among individuals 
with schizophrenia (52-57). Second, increased activity of the complement system has been 
reported in both schizophrenia (58) and autoimmune disorders (59). Finally, proinflammatory 
cytokines have been associated with smaller hippocampal volume in first-episode psychosis 
patients (60) and shown to predict progressive thinning of the prefrontal cortex among 
individuals at clinical high-risk (CHR) for psychosis (i.e., those thought to be in the putatively 
prodromal phase of illness based on their clinical presentation) which was in turn associated 
with transition to psychosis (61). Although activation of the immune system is a core feature of 
all autoimmune disorders, differences in the downstream molecular immune pathways 
activated across the different autoimmune diseases may partly explain why we observed 
significant associations for some, but not all, NNAI disorders in stratified analyses. 
That there might be a shared genetic link between autoimmune disorders and psychosis is 
supported by genome-wide association studies (GWAS) showing that immune regulatory genes 
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are significantly associated with schizophrenia (62). Of particular relevance is the human 
leukocyte antigen (HLA) gene loci, which encodes molecules involved in antigen presentation, 
inflammation, the complement system, and immune responses (63), and has been associated 
with schizophrenia in numerous GWAS studies (64). However, two recent GWAS studies failed 
to show that single nucleotide polymorphisms (SNPs) associated with autoimmune disorders 
(including ankylosing spondylitis, coeliac disease, Graves’ disease, psoriasis, and rheumatoid 
arthritis) were enriched in schizophrenia (65, 66). In contrast, recent studies have reported a 
significant negative SNP-genetic correlation between schizophrenia and seropositive cases of 
rheumatoid arthritis (67) and have identified SNPs with potential pleiotropic effects for 
schizophrenia and rheumatoid arthritis (i.e., where allelic variants of the same gene increase the 
risk for different disorders) (68). Thus, shared genes (particularly HLA genes) might explain the 
negative associations we observed between psychosis and rheumatoid arthritis, but not the 
positive associations we found with other NNAI disorders or the negative association with 
ankylosing spondylitis.  
Infectious diseases are thought to play a role in the aetiology of autoimmune disorders 
(69). A recent study from Denmark indicated that severe infections resulting in hospitalisation 
(including bacterial, viral, and other causes of infection) increase the risk for many autoimmune 
disorders, including, anaemia, coeliac disease, pemphigoid, psoriasis, and rheumatoid arthritis 
(70). Moreover, data from the same population shows that the risk of schizophrenia is even 
higher among those exposed to both an autoimmune disorder and serious infection (7). Thus, 
prior infection could increase the risk for both NNAI disorders and psychosis. However, evidence 
regarding the role of specific pathogens in NNAI disorders is often lacking, and it is possible that 
HLA genes [which have been associated with risk of developing both infections and autoimmune 
diseases (63)] might explain these associations. Moreover, infection is associated with elevated 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Cullen et al. Meta-Analysis of Autoimmune Disorders and Psychosis 
13 
 
 
risk of ankylosing spondylitis and rheumatoid arthritis (70), which in the current study, were 
negatively associated with psychosis. Thus, infection is unlikely to fully explain the observed 
pattern of results. 
There is current interest in the role of neuronal surface autoantibodies (NSAbs) in psychosis 
(71). These antibodies (most of which have been only recently characterised) can induce 
autoimmune encephalopathies, in which psychotic symptoms frequently feature. Antibodies 
directed against the anti-N-methyl-D-aspartate (NMDA) receptor are of particular interest given 
the links between this receptor and psychosis, with a recent meta-analysis finding that these 
NSAbs are more commonly detected among individuals with psychosis relative to healthy 
controls (72). Given that studies of NSAbs are in their infancy, the extent to which they might 
explain the association between autoimmune disorders and psychosis is unclear, particularly 
because no studies to date have examined the prevalence of these antibodies in individuals with 
NNAI disorders. However, encephalopathy associated with autoimmune thyroid disease [also 
known as Hashimoto’s encephalopathy or steroid-responsive encephalopathy associated with 
autoimmune thyroid disease (SREAT)], a condition associated with neurological and psychiatric 
symptoms, has been observed among individuals with Graves’ disease, all of whom presented 
with anti-thyroid antibodies (73). Moreover, a recent study reported that anti-thyroid 
antibodies were present in 13% of patients with schizophreniform disorder (74). Further 
research is needed to determine the extent to which specific autoantibodies might mediate the 
association between the specific NNAI disorders and psychosis that we observed.    
The potential contribution of corticosteroid treatments to the association between NNAI 
disorders and psychosis has received relatively little attention. This is surprising given that there 
is robust evidence of glucocorticoid (i.e., cortisol) abnormalities among individuals with, and at-
risk for, psychosis (75). Moreover, a recent population-based study reported increased risks for 
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schizophrenia spectrum disorders among children/adolescents exposed to glucocorticoid 
treatment (76). Of particular relevance to our findings, corticosteroids are among the most 
common treatment types for psoriasis and pemphigoid (77-79), and some forms of autoimmune 
anaemia (80). However, corticosteroids are commonly used in the treatment of rheumatoid 
arthritis (81), which was negatively associated with psychosis. Thus, the contribution of 
corticosteroids to these associations is currently unclear.   
The negative association we observed between rheumatoid arthritis and psychosis is 
consistent with an earlier meta-analysis (82). Given the late age-of-onset for rheumatoid 
arthritis, it possible that this relationship is partly explained by reduced life expectancy and 
poorer healthcare (leading to lower detection rates) among people with psychosis. Of note, 
rates of cancer, a disease which typically onsets in later life, are also lower among individuals 
with psychosis (83). Consistent with this explanation, juvenile-onset rheumatoid arthritis was 
not significantly associated with psychosis (see Figure 3), although juvenile- and late-onset 
forms differ with regards to symptom severity and treatment (84). Moreover, the fact that 
significant negative associations were found across type A (8, 18, 44), B (41, 47), and C (20) 
studies is at odds with this hypothesis, and instead suggests that a third factor (e.g., genetic 
influences or treatment) may underlie this association.   
One novel finding was the significant negative association observed between ankylosing 
spondylitis and psychosis. Whilst this result is perhaps unsurprising given that ankylosing 
spondylitis was initially thought to be a type of rheumatoid arthritis, the aetiology and 
presentation of these conditions differ substantially (85). Specifically, the age of onset is far 
earlier for ankylosing spondylitis than for rheumatoid arthritis, the former is more common in 
males whist the reverse is true for rheumatoid arthritis, and the disorders are associated with 
different HLA genes (86). Further investigation is needed to identify factors (including other 
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polygenes) common to both disorders that might explain their negative association with 
psychosis. As a related issue, it is interesting to note that we observed positive associations with 
NNAI disorders that are traditionally classified as organ-specific (pernicious anaemia, Graves’ 
disease, pemphigoid, and psoriasis), but negative associations with systemic NNAI disorders 
(ankylosing spondylitis and rheumatoid arthritis) which target multiple organs. However, the 
distinction between organ-specific and systemic disorders is not clear cut, and current 
categorisation is largely based on clinical presentation as opposed to the expression pattern of 
the self-antigen (87).    
Whilst psychotic symptoms are a common neuropsychiatric feature of SLE (88), SLE was not 
significantly associated with psychosis in this meta-analysis; in fact, only one study meeting 
inclusion criteria reported a significant positive association for SLE and psychosis (48). This may 
be because ‘psychoses’ or ‘psychotic manifestations’ in SLE can be acute and transient, and 
therefore not equivalent to a diagnosis of psychotic disorder. In addition, those studies which do 
refer to diagnosed psychotic disorders in SLE are often isolated case reports (89) or studies 
which do not include control groups (90), which were not examined in this meta-analysis.  
Strengths and Limitations 
The vast quantity of data examined (> 25 million individuals) is a major strength of this 
study. Our search strategy was conducted to ensure that we captured all relevant studies, 
including some very early publications. A further strength relates to the fact that we 
systematically investigated the effect of temporality, psychiatric diagnosis, and specific NNAI 
disorders on the magnitude and consistency of effects.  
Some limitations must be noted. First, due to substantial variation in the effect size 
measures reported across studies, we extracted raw data to compute odds ratios. This meant 
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that our effect sizes were not adjusted for important confounding factors that may have 
influenced the association. However, half of the included studies matched cases and controls on 
age and sex (Table 1). Second, as we were keen to utilise all available data, we included studies 
utilising both small clinical samples and large nationwide populations, which may have 
contributed to heterogeneity. Third, as this study was undertaken for as partial fulfilment of a 
Master’s thesis (S.H.), a protocol was not published prior to undertaking the study, as such our 
analysis strategy may have been driven by the data. Fourth, by extracting (and pooling) data for 
individual NNAI disorders, patients with more than one NNAI disorder may have been counted 
twice in the primary (overall) analysis. Fifth, we examined a wide range of disorders classified as 
‘autoimmune’ in the primary papers which included some diseases for which an autoimmune 
basis has not yet been demonstrated. However, to increase validity, we included only NNAI 
disorders were listed as such by the American Autoimmune and Related Diseases Association. 
Finally, despite efforts to obtain data from study authors for all eligible studies, we were unable 
to include data from two large, nationwide studies (7, 23). However, as noted above, it is 
unlikely that including these data would have substantially altered the overall finding.  
Implications 
The finding that psychosis is associated with NNAI disorders (i.e., those which would not be 
expected to directly target the brain, but nonetheless generate substantial immune system 
activation in the peripheral systems that might ultimately affect the brain) is particularly 
important. However, given the range of possible mechanisms that may underlie the significant 
associations that we observed, the considerable heterogeneity across studies, and the fact that 
all effect sizes were small, treatment recommendations based on these findings would be 
premature. Regardless of the mechanism, these findings suggest that careful monitoring of 
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individuals with specific autoimmune diseases (particularly anaemia, Graves’ disease, and 
pemphigoid, as these were the most consistent effects) for early signs of psychosis is warranted.  
With regards to future research, we recommend that (1) studies are designed to better 
disentangle the temporal nature of the association between NNAI disorders and psychosis as 
such studies have demonstrated that both psychosis (7, 23) and depression (91) show 
bidirectional associations with autoimmune disorders; (2) larger studies are undertaken to 
examine the presence of neuronal surface autoantibodies among individuals with psychosis; (3) 
greater efforts are made in large cohort studies to include information on potential confounders 
such as socioeconomic status, adversity, and tobacco use; and (4) studies are undertaken to 
evaluate the effect of corticosteroid treatment on the relationship between NNAI disorders and 
psychosis.  
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FIGURE CAPTIONS 
Figure 1. Search Process 
Figure 2. Results of Overall Meta-Analysis for all Non-Neurological Autoimmune Disorders 
(Except Rheumatoid Arthritis) and Psychosis 
Figure 3. Results of Meta-Analysis for Rheumatoid Arthritis and Psychosis  
 
FIGURE LEGENDS 
Figure 1. Overview of the review process and exclusion reasons. 
Figure 2. Abbreviations: SZ: schizophrenia; PY: psychosis; NSP: non-schizophrenia psychosis; AI: 
autoimmune; Diag: psychiatric diagnosis; HSV: Hypersensitivity vasculitis; SLE: Systemic lupus 
erythematosus; OR: odds ratio; CI: confidence interval. 
a
 autoimmune haemolytic type; 
b
 
hereditary haemolytic type; 
c
 pernicious type; 
d
 acquired haemolytic; 
e
 other hereditary 
haemolytic type; 
f
 childhood-onset. Marker and line colours indicate study design: type A (red), 
type B (blue), type C (pink).   
Figure 3. Abbreviations: OR: odds ratio; CI: confidence interval. All studies examine 
schizophrenia with the following exceptions: Allebeck et al (1985, second row) (30): non-
schizophrenia psychosis; Sundquist et al (2008, first row) (47): non-schizophrenia psychosis; 
Rothermich & Phillips (1963) (44): broadly defined psychosis. Specific rheumatoid arthritis 
subtypes are as follows: Chen et al (2012, second row) (8): juvenile-onset; Eaton et al (2006, 
second row) (9): seropositive; Mors et al (1999, second row) (41): juvenile-onset. Marker and 
line colours indicate study design: type A (red), type B (blue), type C (pink).   
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Table 1. Details and Quality Rating for Studies Meeting Inclusion Criteria 
Author Type 
a
 
Psychiatric 
diagnosis 
(measure) 
Autoimmune 
disorder 
(measure) 
Country 
Design 
(E - O) 
b
 
Data source Sample 
Age 
c
 
(yrs)  
Male (%) 
Matching 
factors 
Outcome 
measure 
Quality 
score 
(max 8) 
Allebeck et 
al. 1985 
(30) 
C 
Schizophrenia 
and Affective 
Psychosis 
(ICD-7) 
Rheumatoid 
arthritis 
(ICD-7) 
Sweden 
Cohort 
(PSY - AI) 
County 
inpatient 
register 
Sz/Psy (N=1,811) 
Cont (N=16,617) 
NS 39.4 None Incidence 5 
Butwicka et 
al. 2015 
(31) 
B 
Psychosis  
(ICD-8, ICD-9, 
ICD-10) 
Childhood 
onset Type 1 
Diabetes 
(ICD-8, ICD-9) 
Sweden 
Cohort  
(AI - PSY) 
National 
diabetes 
register 
AI (N=17,122) 
Cont 
(N=1,696,611) 
AI: 9.3 
 C: NS 
AI: 54.1 
 C: 53.9 
Age, sex, 
country of 
birth 
Incidence 6 
Butwicka et 
al. 2017 
Part A/B 
(22) 
B/C 
Psychosis  
(ICD-8, ICD-9, 
ICD-10) 
Childhood 
onset Coeliac 
disease 
(Biopsy)  
Sweden 
A: Cohort  
(AI - PSY) 
B: Case 
control 
(PSY - AI) 
Histological 
data and 
National 
patient register 
AI (N=10,903) 
Cont 
(N=1,042,072) 
NS 
AI: 37.3 
C: 38.8 
Age, sex, 
country of 
birth 
Incidence / 
Prevalence  
6/6 
Chen et al. 
2011 
(32) 
C 
Schizophrenia  
(ICD-9) 
Pemphigoid 
(ICD-9) 
Taiwan 
Case 
control 
(PSY - AI) 
National health 
insurance 
database 
AI (N=3,485)  
Cont (N=17,425) 
AI: 74.0 
C: 74.0 
AI: 54.8 
 C: 54.8 
Age, sex Prevalence 6 
Chen et al. 
2012  
(8) 
A 
Schizophrenia  
(ICD-9) 
All NNAI 
(N=25) 
(ICD-9) 
Taiwan 
Case 
control  
(AI - PSY) 
National health 
insurance 
database 
Sz (N=10,811)  
Cont (N=108,110) 
NS 
Sz: 54.9 
 C: 49.5 
Age Prevalence 5 
Chu et al. 
2012 
(33) 
A 
Schizophrenia  
(ICD-9) 
Alopecia 
areata 
(ICD-9) 
Taiwan 
Case 
control 
(PSY - AI) 
National health 
insurance 
database 
AI (N=5,117) 
Cont (N=20,468) 
NS 
AI: 50.8 
 C: 50.8 
Age, sex Prevalence 5 
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Author Type 
a
 
Psychiatric 
diagnosis 
(measure) 
Autoimmune 
disorder 
(measure) 
Country 
Design 
(E - O) 
b
 
Data source Sample 
Age 
c
 
(yrs)  
Male (%) 
Matching 
factors 
Outcome 
measure 
Quality 
score 
(max 8) 
Cremaschi 
et al. 2017 
(34) 
A 
Schizophrenia 
(NS) 
All NNAI (N=6) 
(NS) 
Sweden 
Case 
control 
(PSY - AI) 
Hospital 
discharge 
register and 
patient 
interview 
Sz (N=5,278)  
Cont (N=6,485) 
Sz: 53.9 
C: 56.3 
Sz: 59.7 
C: 51.2 
None Prevalence 3 
Eaton et al. 
2006 
(9) 
B 
Schizophrenia  
(ICD-8, ICD-
10) 
All NNAI 
(N=24) 
(ICD-8, ICD-10) 
Denmark 
Case 
control  
(AI - PSY) 
National 
psychiatric and 
patient register 
Sz (N=7,704) 
Cont (N=192,590) 
NS 
Sz: 66.0 
 C: 66.0 
Age, sex Prevalence 5 
Forsti et al. 
2016 Part 
A/B (35) 
B/C 
Schizophrenia  
(ICD-9, ICD-
10) 
Pemphigoid 
(ICD-9, ICD-10) 
Finland 
A: Cohort 
(AI - PSY) 
B: Case 
control 
(PSY - AI) 
National 
register for 
healthcare 
AI (N=4,524) 
Cont (N=66,138) 
AI: 77.0 
C: 73.0 
AI: 40.0 
C: 45.0 
None 
Incidence/ 
Prevalence 
5/5 
Guerin et 
al. 2012 
(19)  
A 
Psychosis 
(ICD-9) 
Psoriasis 
(ICD-9) 
USA 
Case 
control 
(PSY - AI) 
National health 
insurance 
database 
AI (N=106,128) 
Cont (N=106,128) 
AI: 52.1 
 C: 52.1 
AI: 48.5 
 C: 48.5 
Age, sex Prevalence 5 
Huilaja et 
al. 2018 
(36) 
A 
Psychosis 
(ICD-9, ICD-
10) 
Dermatological 
NNAI (N=2) 
(ICD-9, ICD-10) 
Finland 
Case 
control 
(PSY - AI) 
National 
register for 
healthcare 
AI (N=21,690) 
Cont (N=17,488) 
AI: 41.2 
C: 40.5 
AI: 41.5 
C: 41.3 
Age, sex Prevalence 5 
Hutchinson 
et al. 1996 
(4) 
A 
Psychosis 
(DSM-III) 
Systemic lupus 
erythematosus  
(NS) 
Trinidad 
Case 
control 
(PSY - AI) 
Outpatient 
sample 
AI (N=45) 
Cont (N=48) 
NS NS None Prevalence - 
Juvonen et 
al. 2007 
(37) 
B 
Schizophrenia  
(ICD-8, DSM-
III-R) 
Type 1 
Diabetes 
(NS) 
Finland 
Cohort  
(AI - PSY) 
National 
population 
register 
Entire population 
(N=896,175) 
NS NS None Incidence 5 
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Author Type 
a
 
Psychiatric 
diagnosis 
(measure) 
Autoimmune 
disorder 
(measure) 
Country 
Design 
(E - O) 
b
 
Data source Sample 
Age 
c
 
(yrs)  
Male (%) 
Matching 
factors 
Outcome 
measure 
Quality 
score 
(max 8) 
Kridin et al. 
2017 
(38) 
A 
Schizophrenia  
(NS) 
Pemphigoid 
(NS) 
Israel 
Case 
control 
(PSY - AI) 
Health services 
database 
AI (N=1,985)    
Cont (N=9,874) 
AI: 72.1 
C: 72.1 
AI: 40.2 
C: 40.1 
Age, sex, 
ethnicity 
Prevalence 3 
Lauerma et 
al. 1998 
Part A (39) 
B 
Schizophrenia  
(DSM-III-R) 
Rheumatoid 
arthritis 
(NS) 
Finland 
Cohort  
(AI - PSY) 
National 
hospital 
discharge 
database 
AI (N=5,626) 
Cont (N=5,330) 
NS NS None Incidence 4 
Lauerma et 
al. 1998 
Part B (39) 
A 
Schizophrenia 
(DSM-III-R) 
Rheumatoid 
arthritis 
(NS) 
Northern 
Finland 
Cross 
sectional 
(AI - PSY) 
National 
hospital 
discharge 
database 
Sz (N76) 
Cont (N=10,503) 
NS NS None Prevalence 3 
Ludvigsson 
et al. 2007 
(40) 
B 
Schizophrenia 
and Non-
Affective 
Psychosis  
(ICD-8, ICD-9, 
ICD-10) 
Coeliac disease 
(ICD-7, ICD-8, 
ICD-9, ICD-10) 
Sweden 
Cohort  
(AI - PSY) 
National 
inpatient 
register 
AI (N=14,003) 
Cont (N=68,125) 
NS 
Sz: 41.1 
 C: 41.0 
Age, sex, 
area of 
residence 
Incidence 7 
Marrie et 
al. 2018 
(21) 
A 
Schizophrenia  
(ICD-9, ICD-
10) 
Rheumatoid 
arthritis  
(ICD-9, ICD-10) 
Canada 
Case 
control 
(PSY - AI) 
National health 
database 
AI (N=6,350)    
Cont (N=33,584) 
AI: 53.7 
C: 53.7 
AI: 27.8 
C: 27.8 
Age, sex, 
geographic 
region 
Prevalence 8 
Mors et al. 
1999  
(41) 
B 
Schizophrenia  
(ICD-8) 
Rheumatoid 
arthritis (adult 
and juvenile) 
(ICD-8) 
Denmark 
Case 
control  
(AI - PSY) 
National 
psychiatric and 
patient register 
Sz (N=20,495) 
Cont (N=204,912) 
NS 
Sz: 57.6 
 C: 57.6 
Age, sex Prevalence 5 
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Author Type 
a
 
Psychiatric 
diagnosis 
(measure) 
Autoimmune 
disorder 
(measure) 
Country 
Design 
(E - O) 
b
 
Data source Sample 
Age 
c
 
(yrs)  
Male (%) 
Matching 
factors 
Outcome 
measure 
Quality 
score 
(max 8) 
Petrak et al. 
2003 
(42) 
C 
Possible 
Psychosis 
(DSM-IV) 
Type 1 
Diabetes 
(NS) 
Germany 
Case 
control 
(PSY - AI) 
Inpatient 
sample (cases) 
and general 
population 
(controls) 
AI (N=313) 
Cont (N=2,046) 
AI: 28.3 
 C: 30.2 
AI: 62.3 
 C: 50.8 
None Prevalence 4 
Rajkumar et 
al. 2017 
(43) 
A 
Schizophrenia  
(ICD-8, ICD-
10) 
Type 1 
Diabetes  
(ICD-8, ICD-10) 
Denmark 
Cohort 
(PSY - AI) 
National 
patient 
registers and 
prescription 
registry 
Sz (N=8,945)  
Cont 
(N=2,727,565) 
NS 
Sz: 59.7 
C: 50.8 
None Incidence 5 
Rothermich 
& Philips 
1963  
(44) 
A 
Psychosis 
(NS) 
Rheumatoid 
arthritis 
(NS) 
USA 
Case 
control  
(AI - PSY) 
Hospital 
records with AI 
screening 
Psy (N=16,000) 
Cont (N=4,040) 
NS NS None Prevalence 2 
Schmitt & 
Ford 2010 
(45) 
A 
Schizophrenia  
(ICD-10) 
Psoriasis 
(ICD-10) 
Germany 
Case 
control 
(PSY - AI) 
Outpatient 
records 
database 
AI (N=3,147) 
Cont (N=3,147) 
AI: 57.1 
 C: 57.1 
AI: 44.7 
 C: 44.7 
Age, sex Prevalence 6 
Sellgren et 
al. 2014 
(20) 
C 
Schizophrenia  
(ICD-8, ICD-9, 
ICD-10) 
Rheumatoid 
arthritis and 
Ankylosing 
spondylitis 
(ICD-8, ICD-9, 
ICD-10) 
Sweden 
Cohort 
(PSY - AI) 
National 
population 
register 
Entire population 
(N=6,413,683) 
Sz: 44.0 
 C: NS 
Sz: 59.0 
 C: NS 
None Incidence 6 
Shen et al. 
2016 
(46) 
B 
Schizophrenia  
(ICD-9) 
Ankylosing 
spondylitis 
(ICD-9) 
Taiwan 
Cohort  
(AI - PSY) 
National health 
insurance 
database 
AI (N=2,331) 
Cont (N=9,324) 
AI: 36.5 
 C: 36.5 
AI: 64.9 
 C: 63.9 
Age, sex Incidence 7 
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Author Type 
a
 
Psychiatric 
diagnosis 
(measure) 
Autoimmune 
disorder 
(measure) 
Country 
Design 
(E - O) 
b
 
Data source Sample 
Age 
c
 
(yrs)  
Male (%) 
Matching 
factors 
Outcome 
measure 
Quality 
score 
(max 8) 
Sundquist 
et al. 2008 
(47) 
B 
Schizophrenia 
and Psychosis 
(ICD-8, ICD-9, 
ICD-10) 
Rheumatic AI 
(N=3) 
(ICD-8, ICD-9, 
ICD-10) 
Sweden 
Cohort  
(AI - PSY) 
National 
hospital 
discharge 
register 
Entire population 
(N=8,142,857
d
) 
NS NS None Incidence 6 
Tiosano et 
al. 2017 
(48) 
A 
Schizophrenia  
(NS) 
Systemic lupus 
erythematosus 
(NS) 
Israel 
Case 
control 
(PSY - AI) 
Health services 
database 
AI (N=5,018)  
Cont (N=25,090) 
AI: 50.2 
C: 50.2 
AI: 18.0 
C: 18.0 
Age, sex Prevalence 3 
Tu et al. 
2017 
(49) 
A 
Schizophrenia  
(ICD-9) 
Psoriasis  
(ICD-9) 
Taiwan 
Cross 
sectional 
(AI - PSY) 
National health 
insurance 
database 
AI (N=10,796) 
Cont (N=767,327) 
AI: 50.5 
C: 45.9 
AI: 55.2 
C: 48.4 
None Prevalence 6 
Weber et 
al. 2013 
(18) 
A 
Schizophrenia  
(ICD-9) 
All NNAI (N=9) 
(ICD-9) 
USA 
Cross 
sectional 
(AI - PSY) 
Hospital 
discharge 
database 
Entire sample 
(N=2,875,233) 
NS NS None Prevalence 5 
West et al. 
2006 
(50) 
A 
Schizophrenia  
(NS) 
Gastro-
intestinal AI 
(N=3) 
(NS) 
UK 
Case 
control 
(PSY - AI) 
Primary care 
database 
AI (N=18,994) 
Cont (N=95,052) 
NS NS 
Age, sex, 
GP, FU 
time 
Prevalence 5 
Yu et al. 
2017 
(51) 
C 
Schizophrenia  
(ICD-9) 
Psoriasis  
(ICD-9) 
Taiwan 
Cohort 
(PSY - AI) 
National health 
insurance 
database 
Sz(N=4,980)  
Cont (N=19,920) 
Sz: 46.5 
C: 46.6 
Sz: 50.7 
C: 50.7 
Age, sex Incidence 5 
Note. NNAI: non-neurological autoimmune disorders; AI: autoimmune disorder; PSY: psychiatric disorder; Sz: schizophrenia; Psy: psychosis; Cont/C: control group. ICD: 
International Classification of Disease; DSM: Diagnostic and Statistical Manual of Mental Disorders; USA: United States of America; UK: United Kingdom; GP: general 
practitioner; FU: follow-up. 
a
 Type: A: comorbidity of schizophrenia/psychosis and autoimmune; B: autoimmune precedes schizophrenia/psychosis; C: 
schizophrenia/psychosis precedes autoimmune; 
b
 Study design: E: exposure; O: outcome; 
c
 Age: mean or median. 
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Table 2. Results of Meta-Analyses Examining Associations between Non-Neurological Autoimmune Disorders and Psychosis 
Analysis No. studies (type) No. effect sizes (diagnosis) Total N (PSY/AI) OR (95% CI) p Q (p)  I
2
 (95% CI) 
Overall 
a
 27 (A=13; B=8; C=6) 90 (SZ=77; PY=8; NSP=5) 641613 / 540349 1.26 (1.12 to 1.41) <0.001 <0.001 88.08 (85.94 to 89.89) 
Temporal relationship 
a
          
Comorbidity (A) 7 (A=13) 49 (SZ=45; PY=4) 410627 / 328199 1.20 (1.06 to 1.35) 0.003 <0.001 84.80 (80.67 to 88.04) 
PSY precedes AI (B) 6 (B=8) 34 (SZ=28; PY=2; NSP=4) 193594 / 176578 1.43 (1.04 to 1.95) 0.03 <0.001 88.58 (85.10 to 91.25) 
AI precedes PSY (C) 3 (C=6) 7 (SZ=4; PY=2; NSP=1) 37392 / 35572 1.55 (1.01 to 2.38) 0.046 <0.001 87.14 (75.77 to 93.18) 
Psychiatric diagnosis 
a
          
Schizophrenia 20 (A=10; B=6; C=4) 77 (SZ=77) 615498 / 290506 1.21 (1.04 to 1.40) 0.01 <0.001 87.08 (84.50 to 89.23) 
Psychosis (broadly defined) 7 (A=3; B=2; C=2) 8 (PY=8) 14241 / 167104 1.81 (1.39 to 2.37) <0.001 <0.001 85.60 (73.58 to 92.16) 
Non-schizophrenia psychosis 4 (B=3; C=1) 5 (NSP=5) 11874 / 82739 1.38 (1.01 to 1.88) 0.046 0.003 75.34 (39.36 to 89.97) 
Autoimmune disorder          
Alopecia areata 3 (A=2; B=1) 3 (SZ=3) 18777 / 5283 0.90 (0.38 to 2.10) 0.80 0.010 78.26 (29.97 to 93.25) 
Anaemia (pernicious) 3 (A=2; B=1) 3 (SZ=3) 32239 / 1009 1.91 (1.29 to 2.84) 0.001 0.61 0.00 (0.00 to 93.12) 
Ankylosing spondylitis 6 (A=2; B=3; C=1) 7 (SZ=6; NSP=1) 73967 / 63198 0.72 (0.54 to 0.98) 0.04 0.14 37.54 (0.00 to 73.70) 
Coeliac disease 6 (A=2; B=3; C=1) 7 (SZ=4; PY=2; NSP=1) 19507 / 54624 1.53 (1.12 to 2.10) 0.008 0.131 39.08 (0.00 to 74.38) 
Crohn’s disease 4 (A=3; B=1) 4 (SZ=4) 32364 / 20907 0.67 (0.34 to 1.30) 0.23 0.002 79.97 (46.98 to 92.44) 
Graves' disease 3 (A=2; B=1) 3 (SZ=3) 32239 / 7799 1.33 (1.03 to 1.72) 0.03 0.18 41.19 (0.00 to 82.07) 
Pemphigoid 6 (A=2; B=2; C=2) 8 (SZ=6; NSP=2) 20232 / 23585 1.90 (1.62 to 2.24) <0.001 0.322 13.81 (0.00 to 56.59) 
Polymyalgia rheumatica 3 (A=2; B=1) 3 (SZ=3) 23354 / 112 1.63 0.41 to 6.48) 0.49 0.030 71.35 (2.74 to 91.56) 
Psoriasis 8 (A=6; B=1; C=1) 8 (SZ=6; PY=2) 54578 / 141673 1.70 (1.51 to 1.91) <0.001 0.010 61.94 (17.82 to 82.38) 
Rheumatoid arthritis 12 (A=6; B=4; C=2) 17 (SZ=14; PY=1; NSP=2) 244320 / 125090 0.65 (0.50 to 0.84) 0.001 <0.001 79.28 (67.52 to 86.79) 
SLE 7 (A=5; B=2) 8 (SZ=6; PY=1; NSP=1) 48140 / 66545 0.95 (0.65 to 1.39) 0.80 <0.001 76.91 (54.10 to 88.39) 
Type 1 Diabetes 8 (A=4; B=3; C=1) 8 (SZ=6; PY=2) 47208 / 132921 0.79 (0.43 to 1.46) 0.46 <0.001 97.31 (96.10 to 98.14) 
Ulcerative colitis 4 (A=3; B=1) 4 (SZ=4) 32420 / 15526 1.04 (0.69 to 1.56) 0.86 0.08 56.20 (0.00 to 85.48) 
Note. 
a
 Effect sizes for rheumatoid arthritis excluded from analyses. Temporal relationship group: A: comorbidity of schizophrenia/psychosis and autoimmune; B: 
autoimmune diagnosis precedes schizophrenia/psychosis; C: schizophrenia/psychosis diagnosis precedes autoimmune. PSY: psychosis; AI: autoimmune disorder; SLE: 
systemic lupus erythematous; OR: odds ratio; CI: confidence interval; Q: Q statistic from heterogeneity analysis; I
2
: I squared statistic from heterogeneity analysis. Bold 
indicates statistical significance at the 0.05 level (2-tailed).  
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6,718 Studies identified in 
PubMed, EMBASE, Psyclnfo 
after discarding duplicates 
163 Studies added from reference 
lists and manual searching 
6,679 Studies excluded as not 
relevant after preliminary 
review of title and abstract 
202 Studies identified for full text 
review and double rated for 
eligibility 
172 Excluded from meta-analysis: 
30 Studies consisting of 31 
samples included in final 
meta-analysis 
42 Not autoimmune 
39 No control group 
24 Antibody test 
17 Review or commentary 
17 Not psychosis 
8 Unable to obtain paper 
6 Overlapping sample 
5 Genetic association 
4 Not prevalence 
4 Raw data not provided 
3 Incorrect reference 
3 Case study 
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